The recent solutions of the MHC class II crystal structure reveal dimerization of the αβ heterodimers. These dimer of dimers structures may also exist either on resting cells or after engagement by TCR, and may be involved in B cell signaling and up-regulation of co-stimulatory molecules such as B7 which facilitate T cell activation. By combining crystallographic data on HLA-DR1 with the sequence of murine I-A k and refining the resulting structure through energy minimization calculations, we have predicted the contact amino acids expected to stabilize the I-A k dimer of dimers structure. As in HLA-DR1, three salt bridges in I-A k (Dα162-Hβ112, Hα181-Eβ163, Eα183-Hβ113) appear to provide the main interaction. Guided by this structural data, we prepared 45 B cell transfectants representing 20 different class II mutation phenotypes in the contact region containing these salt bridges. We examined their abilities to activate three T cell hybrids. Antigenspecific h4Ly50.5 cells were not greatly affected by changes in the dimer of dimer contact residues. In contrast, autoreactive C8.A3 T cells were very sensitive to changes in this region but presentation of class II of many mutation phenotypes could be rescued by treatments that up-regulate B7-1. The alloreactive hybridoma 2H40.2.5 was less sensitive to changes in the contact residues. A simple model was developed that summarizes the effects of the mutations for the T cells tested. Mutations at Dα162, Eα183, Hα181 and Rβ106 had the largest negative impact, while Dα166, Eα185, Hβ112, Hβ113 and Eβ163 were less disruptive. Results are consistent with mutations interfering with class II interaction with another molecule which might or might not be another class II heterodimer. However, the larger negative impact of α chain mutations in salt bridge pairs suggests that these sites also help maintain some essential conformation of the α chain apart from any possible impact on dimer of dimers stability.
Introduction
Antibody responses to protein antigens require the interaction of antigen-presenting cell (APC) MHC class II molecules bound with agonist peptide and TCR expressed on antigenspecific T cells. The contributions of many laboratories have added complexity to this simple concept. We now know that other molecules such as CD4, CD54 (ICAM-1), CD80 (B7-1), CD86 (B7-2), CD28, CD40, CD154 and CTLA-4 are also required for efficient interactions between the APC and T cell. The interactions possible between these various receptors fine tune the cell physiology of both cell types. In particular, dimerization of class II on B cells signals an increase in Correspondence to: W. F. Wade 3 indicating residues mutated in this study and interchain salt bridges in which these residues are involved. This drawing corresponds to a view from 90% around the right side of the dimer of dimers structure in the left panel, looking downward about 10%. All residues lie more or less in a plane except for Rβ106 which is elevated above the plane of the page. Thus, distances from Dα162 to Hβ112 or Rβ106 are not greatly different.
in the APC membrane is consistent with many aspects of class II immunobiology including both signaling and T cell activation (8, 9) . There are four contact areas in the HLA-DR1 dimer of dimers structure (6) . Two interface areas (contact areas 1 and 2) are located at the membrane-distal end of the dimer of dimers molecule. Contact area 1 involves the DR1 β 1 domain residues 49-55 and area 2 involves the α 1 domain residues 88 and 111. Two other identical interface regions (contact areas 3 and 4) are located extracellularly and proximal to the plasma membrane, 12 Å from the dimer rotational axis. In HLA-DR1 these regions are composed of seven residues of the β 2 domain of one class II molecule that are in contact with seven residues of the α 2 domain of the other class II molecule. Three salt bridges are formed in this interface comprised of Dα158, Hα177 and Eα179 in the α chain, and Hβ111, Hβ112 and Eβ162 in the β chain. The surface area buried between contact regions 3 and 4 is 900 Å 2 .
It was therefore of interest to make mutations in the contact regions between class II heterodimers which are predicted to be involved in dimer of dimers formation and then to assess the impact of these mutations on T cell activation. Once attention has been drawn to specific residues on account of their possible stabilizing effect on dimer of dimers interactions, subsequent experiments do not presume that I-A k dimer of dimers species necessarily exist in substantial numbers or necessarily have a major functional role. Our goal is simply to explore the effects of mutating specific residues on antigen presentation. We focused on residues in contact regions 3 and 4 as they would be located farthest from the TCR-class II interface and comprise the most extensive area of contact in the dimer of dimers. We report the preparation of 45 stable B cell clones representing 20 phenotypes with one or more mutations in contact regions 3 and 4. We have assessed likely structural consequences of these mutations through molecular modeling and evaluated the ability of these mutants to stimulate T cells.
Methods

APC generation, PCR mutagenesis and T cell hybridomas
M12.C3 cells (I-A -, I-E -) that have been co-transfected by electroporation with cDNA encoding the A k α and A k β chains plus DNA from the plasmid pSV2-neo were used as APC in all studies. The cDNA constructs, a gift from Dr Terry Potter (National Jewish Center, Denver, CO), have been described previously (10, 11) . Transfection and maintenance of M12.C3 was done as previously described (12, 13) . PCR mutagenesis (splicing by overlap extension) was used to introduce radical amino acid changes in the class II contact amino acids that comprise contact regions 3 and 4. Oligonucleotide sequences used as primers and the individual PCR amplification conditions are available upon request. To confirm the fidelity of the mutagenesis, nucleotide changes were confirmed by doublestranded DNA sequencing. The class II mutation phenotypes in the αβ heterodimer are referred to by changes in amino acid residue, e.g. Dα162K/wt is a class II molecule possessing an α chain with aspartate 162 replaced by lysine and a wildtype β chain. Specific mutations are listed in Tables 2 and 3. In Fig. 1 all residues mutated in one or more of the 45 transfectants prepared are shown in white.
The T cell hybridomas used in this study have been described in detail (3) (4) (5) 13) . The hen egg lysozyme (HEL) peptide-specific T cell hybridoma h4Ly50.5 and the I-A krestricted autoreactive T hybridoma 2H40.2.5 were gifts from Dr Philippa Marrack (National Jewish Center, Denver, CO). The T cell hybridoma C8.A3 (3) (4) (5) was kindly provided by Dr Tania Watts (University of Toronto, Toronto, Canada). HT-2, a T cell line dependent on IL-2 for growth, was maintained as described and used to assess IL-2 titers (14) .
mAb
The mAb used were 39J, a conformation-specific, A k α A k β -reactive mAb (15) , and 40M, a non-conformationally dependent, anti-A k β mAb (15) . The anti-B7-1 and anti-ICAM-1 mAb were 1G10 and 3F2 respectively, obtained from PharMingen (San Diego, CA), as direct FITC conjugates. FGK115, a rat anti-CD40 mAb, was a generous gift from Dr Ton Rolink (Basel, Switzerland).
Antigen presentation assay
The antigen presentation assay, originally described by Kappler and co-workers, was carried out as previously described (16) . Briefly, in a 96-well microtiter plate 1.0ϫ10 5 APC in RPMI supplemented with 10% FCS, 1 mM sodium pyruvate, 2 mM glutamine, 50 µM 2-mercaptoethanol, 100 U/ ml penicillin, 100 µg/ml streptomycin and 20 µg/ml gentamicin were added to the T cell hybridomas (5ϫ10 4 cells/well). HEL was used at a saturating concentration of 1 mg/ml for antigen presentation to 4hLy50.5, a concentration shown previously to be the break point of the titration curve (13) . For cAMP or anti-CD40 treatments, 1ϫ10 6 APC were cultured overnight (16 h) with 1 mM dibutyrl (db)-cAMP obtained from Sigma (St Louis MO) or with 10 mg/ml affinity-purified FGK115. Antigen presentation cultures were maintained at 37°C in 5% humidified CO 2 for 20 h after which 2-fold serial dilutions of culture supernatants were made for determination of IL-2 titers (12) (13) (14) . IL-2 titers were determined by the reciprocal of the highest 2-fold serial dilution that maintained 80-90% viability of the HT-2 cells. Results are presented as units of IL-2/ml of undiluted supernatant. Only titers which differ by a factor of 4 or more are considered significantly different (12, 13) . Antigen presentation assays were repeated between 2 and 5 times.
Surface expression of I-A k , B7-1 and ICAM-1 Flow cytometric analyses using anti-I-A k mAb directly conjugated with FITC were used to measure the expression of mutant class II. Cells (1.0ϫ10 6 ) were stained with the appropriate reagent for 30 min, washed once in PBS (pH 7.0), examined using a FACScan (Becton Dickinson, Franklin Lakes, NJ) and the data analyzed using the CellQuest system (Becton Dickinson). In Table 2 the fold-difference from wt/wt class II expression of either the 39J or 40M epitope was obtained by dividing the mean fluorescence intensity of the individual mutant by the mean fluorescence value of 9D4 (wt/wt) obtained with either 39J or 40M staining. To measure up-regulation of co-ligands, transfectants were cultured in 24-well plates overnight with or without db-cAMP or anti-CD40 mAb. Treated cells were recovered and washed 3 times to remove db-cAMP or anti-CD40 prior to use in antigen presentation or FACS analysis of B7-1 and ICAM-1 expression. The expression of B7-1 and ICAM-1 was measured on living cells that were gated based on forward and side scatter. Changes in mean fluorescence intensity are reported as increases in fluorescence above the negative control which was gated to contain 5% positive cells.
Statistical analysis of transfectant structure and behavior
For each transfectant clone, data on expression of cell surface molecules (Table 2) , on antigen presentation responses elicited in different T cell assays (Table 3 ) and on structural features of the class II mutations were entered in a spreadsheet, and analyzed using Pearson product moment and Spearman rank order correlation methods (SigmaStat version 2.0; Jandel Scientific, San Raphael, CA) to assess which quantities were most strongly linked to which others. The following structural features of each transfectant clone were evaluated: presence of wildtype residues at individual α chain and β chain mutation sites, presence of a completely wild-type α chain, presence of a completely wild-type β chain, integrity of individual salt bridges, and presence of wild-type residues at both α162 and α183. Each feature was assigned a value of 1 if the wild-type feature was present and a value of zero in its absence. Multiple regression analysis was then performed on the various antigen presentation responses using structural features and surface expression values as independent variables. Molecular modeling of I-A k All molecular modeling was performed on a Silicon Graphics Personal IRIS 4D/25 workstation using the DREIDING II force field and Biograf software (BIOSYM/Molecular Simulations, San Diego CA). The current model representing the dimer of dimers for murine MHC class II I-A k was constructed using the atomic coordinates obtained from the X-ray crystal structure of the corresponding HLA-DR1 complex (17, Protein Data Base accession no. 1DLH) as a template. The initial step of the modeling procedure required the alignment of the amino acid sequences (Swiss Protein Data Bank) for the α and β chains of the I-A k protein (P01910 and P06343 respectively) with the corresponding sequences for the α and β chains of the HLA-DR1 protein (P01903 and P13758 respectively). These sequences were aligned using the Gap alignment routine contained within the Genetic Computer Group sequence analysis package (18) .
The final model included residues 3-182 and 6-190 for the I-A k α chain and β chains respectively, with corresponding amino acid sequence similarities of 73 and 79% and identities of 55 and 68%. Using the crystal structure of the HLA-DR1 protein as a template, the homologous structure of the α and β chains of the I-A k protein was then constructed using computeraided site-directed mutagenesis in order to replace the nonhomologous residues present on the template with those of the I-A k protein. A total of only three amino acid additions or deletions were required to convert the template structure into the current model. In each case the additions or deletions were performed in loop structures without perturbing the β sheet structure of the template protein.
An initial model of a single αβ heterodimer was constructed.
The energy of this I-A k heterodimer was then minimized to convergence as a preliminary step before subjecting the structure to molecular dynamics calculations. While maintaining the atomic positions in all α helices and β sheets, the loop structures within the minimized structure were first subjected to 100 psec of molecular dynamics calculations followed by energy minimization as previously described (19) . To complete the final form of the dimer of dimers model for the I-A k protein, the atomic coordinates of two single αβ heterodimers were then superimposed onto the backbone coordinates of the crystal derived coordinates for the tetrameric HLA-DR1 structure. The energy of the new tetrameric complex was then minimized to convergence. To further refine the interactions between the various subunits, the entire tetrameric complex was then subjected to further molecular dynamics calculations (50 psec) followed again by energy minimization to relieve any side chain-side chain strain between the subunits in the complex.
Results
Molecular modeling of I-A k suggests that it is structurally very similar to HLA-DR1
To determine whether I-A k might be capable of existing as a dimer of dimers, we constructed a computer model of this structure. We chose to homology model I-A k based on the HLA-DR1 structure of Brown and co-workers (7). The initial structure was derived by combining HLA-DR1 atomic coordinates with the I-A k sequence as described in Methods. This trial structure was then minimized to convergence. The most important result of this modeling is the degree of structural similarity predicted to exist between HLA-DR1 and I-A k . This is most clearly seen through the effects of energy minimization/molecular dynamics calculations. Before energy minimization, the trial structure is assumed to have the precise protein folding of HLA-DR1. After minimization, it has adopted the folding appropriate to the actual I-A k sequence. Looking at only the backbone atoms, the average root mean square (r.m.s.) difference for wild-type I-A k before and after molecular dynamics calculations was 2.7 Ϯ 0.3 Å averaged over the four chains. Thus, there is essentially no predicted difference in the overall folding of I-A k and HLA-DR1. This final structure predicted for I-A k is illustrated in Fig.  1 (left) where the white residues represent sites of mutations in one or more transfectants. Inspection of contact region 1 of the refined I-A k dimer of dimers structure shows it to be virtually identical to that reported for HLA-DR1. In both cases the region is an identical stretch of β 1 domain amino acids, AVTELGR, corresponding to positions β49-55 in HLA-DR1 and to β51-57 in I-A k . Contact region 2 represents α 2 domain contacts in the center of the molecule. Surprisingly, residues Eα89 and Rα145 in I-A k form a salt bridge in virtually the same position as that formed in HLA-DR1 by Eα88 and Kα111. Contact regions 3 and 4, representing the interface between α and β chains on alternate heterodimers, are complex and it is difficult to decide how many amino acids the group of contact residues should be taken to include. Nonetheless, one could fairly include the homologs of all residues indicated as interfacial in DR1, i.e. α161, α162, α166, α179,α181, α183, α185, β106, β112, β113, β143, β144 and β163. The salt bridge structure of HLA-DR1 is maintained in I-A k with the caveat that Rβ106 is virtually as close to Dα162 as is Hβ112.
The I-A k mutants Dα162K/wt, Dα162K/Rβ106E, Eα183K/ Rβ106E and Hα181D/Eβ163K were also subjected to similar structural analysis. In all cases the r.m.s. deviation of backbone atoms of the energy-minimized mutant from the unminimized wild-type I-A k (i.e. HLA-DR1) was 2.7 Ϯ 0.3 Å, the same value as for the wild-type protein. This provides further computational justification for the notion that I-A k and these various point mutants all share the tertiary and quaternary structure of the HLA-DR1 dimer of dimers.
The predicted I-A k structure, like HLA-DR1, exhibits three salt bridges central to dimer of dimers interactions Analysis of the DR1 crystal structure suggests that one of the forces maintaining the stability of the tetrameric complex derives from inter-subunit salt bridges between charged residues on α 2 and β 2 domains located on complimentary dimers. The HLA-DR1 crystal exhibits three salt bridges in contact regions 3 and 4: Eα158 paired with Hβ111, Hα177 paired with Eβ162 and Eα179 paired with Hβ112 (7). Similarly, examination of the model of the I-A k dimer of dimers refined by molecular dynamics also reveals three interchain salt bridges in contact regions 3 and 4 comparable in position to those described for the HLA-DR1 protein. Thus, the I-A k salt-bridges include Dα162 paired with Hβ112, Hα181 paired with Eβ163 and Eα183 paired with Hβ113. Differences in the numbering of the salt bridge residues between HLA-DR1 and I-A k arise from additional residues present in the N-terminal regions of the A k α and A k β chains. These latter residues along with Dα166, Eα185 and Rβ106 comprise the residues mutated in our study ( Fig. 1, right) .
Modeling predicts both wild-type I-A k and various mutants to exhibit substantial favorable energies of dimer-dimer interaction Because of substantial computation time required for structural calculations, we examined only the wild-type structure and four mutants with individual salt bridges disrupted. As stated earlier, like wild-type I-A k , these mutants adopted almost exactly the same overall structure as HLA-DR1. These calculations permitted us to assess the approximate energies of interaction between individual α and β chains in the αβ heterodimers and between αβ heterodimers in the dimer of dimers. These results are shown in Table 1 . The average α-β interaction energies are calculated to be -924 Ϯ 7 kcal/(mol αβ) in the wild-type protein and range from -894 Ϯ 44 to -1008 Ϯ 40 kcal/(mol αβ) for the various mutants. The differences between the various values are not statistically significant. All proteins exhibited substantial negative (favorable) energies of dimer-dimer interaction. The αβ-αβ interaction energies are -1099 kcal/[mol (αβ) 2 ] in the wild-type protein and range from -973 to -1299 kcal/[mol (αβ) 2 ] in the mutants. The studies of Shafer and Pierce (23) can be taken to suggest that both αβ and (αβ) 2 are simultaneously present on B cell surfaces. The equilibrium constant for dimer of dimers formation might then be expected to lie between, say, 0.1 and 10. This is because if the equilibrium constant were appreciably larger, then only (αβ) 2 dimer of dimers would have been observed and, if it were smaller, only αβ heterodimers would have been detected. Because an equilibrium constant K is related to the standard state free energy change ∆A°for its a This value represents the mean Ϯ SD of separate calculations on the two αβ heterodimers comprising a dimer of dimers unit. Because each calculation is independent and involves input of random molecular fluctuations, results are expected to differ. associated reaction by ∆A°ϭ -RT ln K, the corresponding range of free energies for dimer of dimers formation would be -1.4 to ϩ1.4 kcal/mol. In contrast the (internal) energies calculated for dimer-dimer association and mentioned above center around -1000 kcal/mol. These favorable interaction energies must thus be almost completely compensated by a large unfavorable T∆S since ∆A ϭ ∆E -T∆S at constant temperature and volume. Because there is no way to evaluate such entropic factors, these calculations cannot be used to predict how mutations might affect dimer of dimer equilibria. However, they clearly indicate that dimer of dimers interactions in wild-type and mutant I-A k are strongly favored on energetic grounds.
I-A k -containing mutations in dimer of dimers contact residues are generally well-expressed on the plasma membrane We analyzed 45 individual stable B cell transfectant clones that expressed 20 different class II mutant phenotypes within the residues of the third and fourth contact regions. Typically two to three clones of each mutant phenotype were analyzed by FACS using the conformation-specific mAb 39J recognizing A k α A k β and the non-conformationally dependent mAb 40M recognizing A k β alone. Table 2 presents these expression levels. In general, class II molecules that contain mutations in dimer of dimers contact residues were expressed on the plasma membrane at levels at or above that of wild-type I-A k on 9D4 cells. Only three of the 45 clones analyzed, i.e. clones 28.24, 49.8 and 13.18.8, had class II levels Ͻ50% of 9D4 cells, as measured with 39J mAb. In these cases, other clones of the same mutation phenotypes were well expressed.
We have attempted to identify free dimer of dimers levels on these transfectants by Western blot analysis. This would permit direct assessment of effects of mutations on inter-αβ interactions. Unfortunately, even for the wild-type I-A k , if free dimer of dimers species exist at all, they apparently exist at quite low levels (data not shown). Single particle tracking methods provide an alternate means of detecting dimer of dimers species and we are evaluating the feasibility of such measurements on our system. Mutations in class II dimer of dimers contact residues have limited effects on antigen presentation to an antigen-specific T cell clone It was of interest to determine how efficiently class II molecules with mutations in the dimer of dimers contact residues could a Using a FACScan, transfectants were analyzed for surface expression of mutant class II using either directly conjugated 39J, a conformation specific, A k α A k β -reactive mAb, or 40M, a non-conformational dependent, anti-A k β mAb. Expression values for class II are reported normalized with respect to the wt/wt transfectant 9D4. Bold values indicate expression less than half that of wild-type I-A k on 9D4 cells.
b The expression of B7-1 on resting and db-cAMP-treated transfectants was measured by a FACScan. B7-1 levels are reported as mean fluorescence (arbitrary units) before and after cAMP treatment. Bold values indicate expression less than half that of B7-1 on comparably treated 9D4 cells.
c The expression of ICAM-1 on resting and cAMP-treated transfectants was measured by a FACScan. ICAM-1 levels are reported as mean fluorescence (arbitrary units) before and after anti-CD40 treatment.
present antigen to T cell clones of various specificities. The T cell hybridoma h4Ly50.5 is specific for I-A k plus HEL peptide and we have shown it to be sensitive to structural changes in class II. In particular, class II molecules lacking the cytoplasmic domain of the α chain do not stimulate h4Ly50.5 efficiently (13) . Table 3 indicates IL-2 production elicited from h4Ly50.5 cells by the various transfectants each incubated with a single 1 mg/ml concentration of HEL optimal for presentation by 9D4 cells. The vast majority of the panel of transfectants, 38 clones among 45 or 85%, stimulated levels of IL-2 secretion from h4Ly50.5 that did not differ significantly from wild-type. Bold values in Table 3 indicate clones where b The IL-2 titers represent the responses of the T cell to untreated APC or to APC that were treated overnight with either db-cAMP or anti-CD40 mAb.
antigen presentation to h4Ly50.5 cells was significantly reduced. The individual clones of several mutation phenotypes that did not optimally stimulate h4Ly50.5 also exhibited either low B7-1 (clone 49.13), low ICAM-1 (clone 31.18), low class II expression (clone 49.8), or combinations of these factors (clones 28.8 and 28.24).
We have measured the expression of HEL peptides bound to I-A k on several transfectant cells under our assay conditions (data not shown). There are essentially no differences in these numbers among transfectants when corrected for class II expression. Thus it seems likely that the fundamental effects of the mutations we introduced arise from factors other weakened peptide-class II interactions. Nonetheless, the HEL system provides a number of opportunities for detailed future studies.
Mutations in contact region salt bridge residues Dα162 or Eα183 inhibit antigen presentation to an alloreactive T cell 2H40.2.5 is an alloreactive T cell hybridoma not having a strict activation requirement for B7 (4, 5) . It is intermediate between the antigen-specific h4Ly50.5 and the autoreactive C8.A3 in its sensitivity to class II mutations in the contact residues of the dimer of dimers region. 2H40.2.5 cell IL-2 production elicited by transfectants is summarized in Table  3 . As an average over two experiments, this T cell exhibited substantial responses to 68% of the transfectants expressing class II mutants. Shading in Table 3 indicates clones where antigen presentation to 2H40.2.5 cells was significantly low, i.e. Ͼ4-fold below that of 9D4 cells. These clones are typically characterized by substitutions at α chain residues Dα162 and Eα183, whether or not paired with β chain mutations. Mutations at Hα181 or Rβ106 also exhibit negative effects that are more variable. In some cases individual clones of a particular mutation phenotype stimulated T cells more effectively than others of that phenotype. In such cases enhanced ability to stimulate 2H40.2.5 correlated with increased expression of class II (e.g. clone 28.1, Dα162K/wt), B7-1 or ICAM-1 (e.g. clone 29.21.5, Eα183K/wt) by that clone.
To explore the results of enhanced co-ligand expression on APC, cells were treated overnight db-cAMP. This treatment typically increased B7-1 expression by 2-to 4-fold over control samples of the same clone, though both larger and smaller increases were observed ( Table 2 ). The treatment also improved the ability of APC to stimulate 2H40.2.5 but this enhancement was generally lower than the 8-fold observed for 9D4 cells expressing wild-type I-A k (Table 3) . Noteworthy exceptions to this were clones 28.8 and 28.24 of phenotype Dα162K/wt where cAMP treatment enhanced antigen presentation significantly. We also tested the ability of CD40 engagement via anti-CD40 mAb, which increases both B7-1 and ICAM-1 expression (20, 21) , to facilitate activation of 2H40.2.5 by transfectants expressing mutations in I-A k dimer of dimers contact residues ( Table 1) . Ligation of CD40 enhanced activation of 2H40.2.5 in several clones, but these increases only rarely exceeded the 4-fold increase observed for wild-type I-A k .
Antigen presentation to an autoreactive T cell can be rescued by cAMP or anti-CD40 in some dimer of dimers mutants C8.A3 is an autoreactive T cell hybridoma that has been used extensively for studying antigen presentation by signalingdeficient I-A k molecules (3) (4) (5) . Studies by Watts and colleagues (4, 5) have demonstrated that C8.A3 is critically dependent on B7-1 and ICAM-1 expression on the APC for optimal activation. Thus activation of C8.A3 cells would be expected to reflect effects of specific class II mutations linked to ICAM-1 or B7-1 expression. Table 3 shows that C8.A3 is extremely sensitive to mutations in the class II dimer of dimers contact regions 3 and 4 of the APC. 9D4 cells expressing wt/ wt I-A k stimulate 80-160 U of IL-2 from C8.A3, while only 33% of the 45 transfectant clones can activate C8.A3 as effectively as 9D4. Mutations in the class II α and β chains behave differently in stimulating this T cell. Transfectants expressing wild-type α chains plus β chains with combinations of the mutation phenotypes Eβ163K, Dβ112H or Dβ113H can stimulate C8.A3 if the class II levels are sufficiently high. In contrast, transfectants that express I-A k with mutations in the α chain are deficient in their ability to activate C8.A3 independent of class II levels. Transfectants expressing contact region mutations in both chains also exhibit reduced stimulation of C8.A3 with one interesting exception. This exception is Hα181D/Eβ163K of which both clones examined exhibit virtually normal antigen presentation to all three T cell lines. This phenotype is the sole example in this study of a compensating double mutation interchanging positively and negatively charged residues on a pair of sites involved in a dimer of dimers salt bridge, thus presumably permitting the formation of normal salt bridges in the class II dimer of dimers structure.
Because C8.A3 stimulation requires optimal expression of B7 on the APC, we again treated the panel of transfectants overnight with 1 mM db-cAMP to induce B7-1 expression (4,5). Among clones eliciting significantly low responses by C8.A3 cells, cAMP treatment rescued the ability of nine clones among 35 to stimulate C8.A3. Those transfectants that were consistently unable to stimulate C8.A3 even following cAMP treatment were typically characterized by α 2 domain mutations Dα162K, Eα183K or Hα181D, or by the β 2 domain mutation Rβ106E. The α chain mutations inhibited antigen presentation regardless of whether the β chain was wild-type or mutant, while the Rβ106E substitution potentiated the effects of α chain mutations. We also examined the ability of CD40 ligation to enhance presentation to C8.A3. Overnight incubation with anti-CD40 rescued antigen presentation in 10 of 27 poorly presenting clones. In general, the transfectants that were able to activate C8.A3 following db-cAMP treatment were also rescued with anti-CD40 treatment (Table 3) . Similarly, the transfectants that were to unable to activate C8.A3 following db-cAMP were also unable to activate C8.A3 following treatment with anti-CD40.
Low expression of B7-1 and ICAM-1 on transfectants correlates with specific mutations in the dimer of dimers contact residues Because treatment of transfectants with db-cAMP or anti-CD40 rescued activation of C8.A3 and, in selected cases, 2H40.2.5, we measured the levels of B7-1 and ICAM-1 before and after db-cAMP treatment ( Table 2 , right-hand columns). The mean fluorescence representing B7-1 expression on the individual transfectants without and with db-cAMP treatment is shown. B7-1 was well expressed on resting transfectants, only two clones among 45 (50.7 and 52.6, bold values in Table 2 ) expressed B7-1 at levels less than the 50% of the parent M12.C3 cells. Typically APC showed a bimodal histogram for B7-1 before db-cAMP treatment and a unimodal one after treatment (data not shown). Transfectants for which db-cAMP treatment rescued the ability to activate C8.A3 and 2H40.2.5 generally had, after such treatment, a significant increase in B7-1 above the resting level (compare Tables 2 . In contrast, the B7-1 expression level on a group of APC that was unable to activate C8.A3 stayed at a level comparable to cells not treated with db-cAMP. A few transfectants exhibited intermediate behavior: six clones characterized by Hα181D up-regulated B7-1 in response to cAMP but still did not present antigen to C8.A3. Anti-CD40 treatments also up-regulated B7-1 but not for the transfectants that were unresponsive to db-cAMP (data not shown).
ICAM-1 levels were more variable on the transfectant clones ranging from~0.1 times that of parent M12.C3 cells (e.g. clone 29.7, Eα183K/wt, or clone 33.14, Dα162K/Rβ106E) to 5-10 times that level (e.g. clone 42.6, Eα185K/wt, or clone 47.13, Dα166K/Hβ112D, Hβ113D). Treatment of transfectants with db-cAMP overnight had little effect on ICAM-1 levels while anti-CD40 treatment increased ICAM-1 on those transfectants on which B7-1 was also up-regulated by anti-CD40 (data not shown). Figure 2 shows how transfectants' abilities to elevate B7-1 or to express ICAM-1 relate to their antigen presentation to C8.A3 autoreactive T cells. IL-2 production by C8.A3 cells stimulated by APC treated overnight with db-cAMP is shown on both y-axes. In the left panel the x-axis is the increase in B7-1 expression on transfectants treated overnight with dbcAMP while in the right panel the x-axis indicates ICAM-1 levels on resting cells. In both panels open circles indicate clones whose antigen presentation without cAMP pretreatment did not differ significantly from cells expressing wild-type class II. Open triangles indicate cells with low presentation before cAMP treatment but comparable to wild-type controls after cAMP, i.e. rescued by cAMP. Black diamonds indicate clones with unconditionally low presentation, i.e. not rescued by cAMP, which contain mutations at α162 and/or α183. Gray squares indicate non-rescuable clones with all other mutations, most commonly containing Hα181D (six clones among nine) and/or Rβ106E (four clones). Together these figures demonstrate that mutations at sites α162 or α183 give rise to strongly impaired antigen presentation to C8.A3 cells which is associated both with low resting ICAM-1 levels and with an inability to up-regulate B7-1.
T cell antigen presentation responses are statistically correlated with class II, B7-1 and ICAM-1 expression on APC Because of the large numbers of class II phenotypes, wildtype and mutant transfectant clones, and different antigen presentation assays available, we felt that statistical analysis of transfectant properties might be valuable. We hoped it might suggest significant relations between transfectant expression of cell surface molecules, antigen presentation responses elicited in different T cell assays (Table 3) and structural features of particular mutants which might not be apparent from visual inspection of the data. As described in Methods, we calculated the Pearson product moment correlation coefficients between all pairs of these various quantities. We then evaluated the probability that the observed correlation coefficient could have been obtained in measurements on 46 clones if a pair of quantities was actually unrelated. These probabilities are shown in Table 4 with actual Pearson correlation coefficients being given in parentheses. Qualitatively similar results (not shown) were obtained using Spearman rank order correlation. Low values in the table indicate a high probability that the quantities in the particular row and column are related. Values Ͻ0.05 are commonly considered highly significant. Table 4 thus shows that the average level of class II expression on untreated APC is significantly correlated with activation of all three T cells; however, APC treatment with either cAMP or anti-CD40 reduces this correlation substantially. Similarly, both B7-1 expression after cAMP treatment and resting levels of ICAM-1 seem to be significantly correlated with the responses of all three T cells, but cAMP and anti-CD40 treatments of APC do not have consistent effects. An observation not included in Table 4 is that expression levels of B7-1, both in resting cells and after treatment with cAMP, are strongly positively correlated with expression of ICAM-1 in that particular transfectant, probabilities that these quantities are actually independent being 0.005 and 0.000 respectively. This observation derives solely from cell surface properties of the various transfectants, not from any T cell activation phenomena, and so suggests that expression of these two ligands must be linked to some extent. Mutations at any site generally correlated negatively with T cell antigen presentation responses, but correlation coefficients between particular mutations and responses varied widely in ways that could not easily be rationalized. Mutations Dα162K and Eα183K yielded the most pronounced effects. In particular, when the presence of wild-type residues at both α162 and α183 was evaluated as a single structural feature, all T cell responses showed positive correlations with this feature, the significance being Ͼ98% (Table 4 ).
A simple model predicts effects of particular class II mutations in the various antigen presentation assays Examination of assay results in Table 3 suggested that, whatever antigen presentation assay was examined, mutations at one site had approximately consistent effects relative to mutations at other sites. For example, mutations Dα162K and Eα183K always had somewhat larger effects on antigen presentation responses than mutation at Rβ106 and much larger impacts than changes at Eα185. However, the consequences of any particular mutation varied with the antigen presentation assay, e.g. C8.A3 cells being generally more sensitive to all class II structural changes than 4hLy50.5. This suggested that the whole pattern of results might be rationalized by assigning one set of effects to individual site mutations and scaling these effects to each assay system examined. We found that the following single model describes all these responses well: log r ij ϭ log f j ϩ log c i ϩ Σ sites l log K l where r ij is the response, normalized to that of wild-type class II, elicited by the i th transfectant clone in the j th antigen presentation assay, f j is the factor reflecting the overall sensitivity of the particular assay to class II mutations, c i is the expression level of class II on the i th transfectant and the various K l are constants characteristic of the particular residue located at mutation site 2 in the transfectant, wildtype residues being assigned a value of 1. Thus the only adjustable parameters are one f j for each of the seven different T cell assays and one K l for each of the eight mutation sites. As will be covered in the Discussion following, this model would be appropriate if the critical event in antigen presentation were the interaction of class II molecules of surface concentration c with another species, either on the APC or on the T cell, and where mutations at particular class II sites had independent, multiplicative effects on the affinity of this interaction. The various antigen presentation results were analyzed simultaneously by linear least squares methods according to the above model. The values of f j and K l consistent with all 322 measurements are shown in Table  5 and Fig. 3 shows the normalized responses observed experimentally plotted versus those calculated from Equation (1) . It is clear that stimulation capacities of the various transfectant clones are surprisingly well predicted, given the simplicity of the model. The correlation coefficient of this regression is ϩ0.99 and the SD of log r is 0.76, indicating that responses are predicted to within ϩ214%, -53%, well b Each column tabulates the response elicited by a class II molecule bearing the particular mutation with respect to a comparable molecule with the corresponding wild-type residue after correction for the mutation sensitivity f j of the particular assay. The uncertainty of individual fitted constants is 1 SD established by linear error estimation (28) . Fig. 3 . Observed normalized T cell responses to antigen presentation by transfectants plotted versus calculated responses from Equation (1). Seven different assays are shown, points from each assay being plotted with a distinct symbol. Observed responses are plotted on the y-axis while results calculated from Equation (1) are plotted on the x-axis using the values for f j and K l presented in Table 5 . The correlation coefficient for the plot is ϩ0.99 and the SD of individual points is ϩ214%, -53% which is comparable to the estimated uncertainty in individual IL-2 measurements.
with the uncertainty of individual assays. We also evaluated site-specific effects for individual antigen presentation assays. In these cases K's at different sites typically had the same ratios as those obtained in the global fit and the quality of these individual fits were not significantly better than when all assays were analyzed in terms of a single set of K's (data not shown).
Inspection of Table 5 bears out what is apparent from visual examination: mutations Dα162K (K ϭ 0.10) and Eα183K (K ϭ 0.11) cause the smallest T cell activation, i.e. IL-2 production. Thus these mutations have the largest negative impacts, while the substitution Rβ106E is only slightly less significant (K ϭ 0.15). All other mutations have substantially lower effects (K ϭ 0.31-0.69). It is interesting that the pair of salt bridge-perturbing mutations Hβ112D and Hβ113D, which were always introduced as a pair, had a lower effect together (K ϭ 0.69) than any single mutation.
Discussion
The crystal structures of human HLA-DR1 (7) and murine I-E (6) class II molecules indicate that class II molecules crystallize as dimers of dimers. Dimerization of class II or cognate interactions with T cells signals the B cell (3) (4) (5) 22) to upregulate co-stimulatory molecules such as B7. These observations, together with other published data (8, 9) , suggest that formation of class II dimer of dimers structures in the APC membrane during cognate interactions might provide signals or structures that optimize antigen presentation. Direct biochemical and biophysical evidence exists for the presence of small amounts of class II dimer of dimers structures on APC (23, 24) . Unfortunately, the preceding studies employed methods (single particle tracking and radioiodination of cell surface proteins) that are not generally applicable for evaluating the functional presence or absence of dimer of dimers class II molecules on cells. Moreover, the number of free dimer of dimers species in the cell membrane does not necessarily relate to the number of dimer of dimers species formed upon interaction with the TCR. Given this situation, examining the functional consequences of a large number of mutations which might be expected to alter the affinity of inter-αβ interactions provides the next best means of assessing whether such interactions may be important in antigen presentation. If mutations at dimer of dimers contact sites strongly interfere with some cellular process while mutations in other regions do not, then this provides strong evidence supporting though not confirming a role in that process for some form of interaction between class II heterodimers.
We have therefore performed a comprehensive structurefunction analysis of the third and fourth contact areas of the murine I-A k dimer of dimers. The antigen-specific T cell 4hLy50.5, a cell line with strict activation requirements for structurally intact I-A k molecules, is substantially unaffected by mutations in the dimer of dimers contact residues of I-A k . However, the autoreactive T cell hybridoma C8.A3, that requires B7-1 and ICAM-1 expression by the APC for optimal activation, is extremely sensitive to mutation of many of the amino acids that comprise contact regions 3 and 4 of I-A k . However, some mutation phenotypes can present antigen to C8.A3 if B7-1 is elevated trans to class II signaling. Another group of mutants, typically containing Hα181, cannot present antigen even given artificially elevated B7-1 levels. A final group of class II mutation phenotypes is consistently unable either to up-regulate B7-1 upon cAMP treatment or to activate C8.A3 after such treatment. Such clones typically possess α chain mutations at Dα162 or Eα183 which are salt bridge partners of β chain residues Hβ112 and Hβ113 respectively. Together these residues comprise the most distal salt bridges of contact regions 3 and 4, and are highly conserved in class II molecules of mouse and man (26) .
Our results support and extend those of Goodman and coworkers (25) who made mutations in the salt bridge residues in the second contact region of the DR3 dimer of dimers α 1 domain and evaluated antigen presentation to a panel of T cells. They found, as we have, that substitution of one salt bridge partner, Eα88 in their study, but not the partnered residue Kα111, resulted in class II molecules that failed to activate alloreactive and antigen-specific T cells lines.
Visual inspection of assay results suggests that particular mutations have generally consistent relative effects on different antigen presentation assays. Thus the mutations Dα162K and Eα183K typically yield the largest negative impact on any assay. This general behavior is confirmed by detailed statistical analysis. Actual responses in seven different T cell assay systems can be predicted ϩ214%, -53% and with a correlation coefficient of ϩ0.99 by Equation (1) , where a single set of multiplicative effects are assigned to individual site mutations and where these effects are scaled to each assay system by a single constant. One physical model which would give rise to this would be if the critical event in antigen presentation were the interaction of class II molecules with another species, either on the APC or on the T cell, and where mutations at particular class II sites had independent, multiplicative effects on the affinity of this interaction. This other molecule might be another class II molecule, if dimers of dimers species are critical, some other APC protein species which must interact with class II during antigen presentation or the TCR itself.
The biological explanation of the structural effects revealed by the statistical analysis could be 2-fold. First, mutations in the contact region could weaken interactions between αβ heterodimers. This could either make more difficult the aggregation of class II molecules, for example, upon engagement by TCR or it could reduce the steady-state concentration of dimer of dimers molecules. Both would affect low-affinity TCR interactions and, in addition, class II signaling downstream might be compromised as well. Downstream class II signals that could be affected are cAMP generation and PKC translocation. The resulting gene activation or changes in B cell biology are required for efficient antigen presentation (2) (3) (4) (5) 22) . Alternatively, mutations, particularly those at Dα162 or Eα183, might produce allosteric changes in the class II α chain preventing productive T cell interactions or signal transduction through class II. Thus, in the first case, mutations interfere with interactions between pairs of αβ heterodimers that form the dimer of dimers. In the second, the mutation effects are localized to the particular αβ heterodimer where the mutated residue resides. The strong inhibition of antigen presentation to various T cells by mutations in presumed salt bridge residues points to a role for dimer of dimers interactions. However, the perhaps stronger effects caused by mutating α chain vis à vis β chain partners of salt bridges (Tables 3 and 5) suggest that chainspecific, structural effects of mutations must also be involved.
The mutations we examined do not seem to grossly perturb class II structure. For example, binding of 39J, a mAb specific for an epitope formed by steric interaction of A k α A k β , is retained. Further support for the lack of gross allosteric changes or substantial weakening of peptide binding affinity is the fact that most mutant class II molecules are able to activate h4Ly50.5, a T cell that is sensitive to structural changes in class II (13) . We have not directly investigated whether allosteric changes in the class II mutants have compromised their interaction with TCR. Nonetheless, we do not feel gross allosteric changes can explain antigen presentation defects in all mutation phenotypes as many can be rescued by treatments that increased B7-1 expression, suggesting that the capacity of TCR and class II to bind is intact. A direct resolution of this issue awaits direct measurements of the affinity of mutant class II for TCR.
As argued above, mutations in class II dimer of dimers contact residues could theoretically prevent stable dimerization. The effect of this would be 2-fold, i.e. potential loss of interaction with TCR or loss of signal transduction to the B cell. Transfectants that express mutations at Dα162 and Eα183 do not present antigen to C8.A3. If lack of B7 expression, regardless of the mechanism, were the explanation for poor antigen presentation, then it would be expected that the addition of dbcAMP or treatment with anti-CD40 mAb, both of which induce B7-1 expression, should rescue presentation. While these treatments were able to rescue antigen presentation in many transfectants, the transfectants expressing class II with Dα162 K or Eα183K mutations were not rescued and were unable to upregulate B7-1 in response to these stimuli. The possibility that a cloning artifact explains the low B7-1 and the inability to elevate it seems unlikely to us, since this phenotype is strongly associated with multiple clones of the Dα162 K or Eα183K class II phenotypes. We do not understand why this subset of clones cannot up-regulate B7-1, but it is not due to an intrinsic nonresponsiveness to db-cAMP. Transfectants that express class II with mutations in either Dα162K or Eα183K up-regulated B7-2 expression in response to db-cAMP treatment (W. F. Wade, pers. observation). It is not clear why B7-2 cannot activate C8.A3 but may be linked to the fact that, after db-cAMP treatment, B7-2 is expressed on dead cells. A particular cohort of class II transfectants thus exhibits both lack of up-regulation of B7-1 by two different signaling pathways and low level of ICAM-1, expression of these co-ligands appearing to be somewhat linked in M12.C3 cells as noted earlier. This is suggestive of an altered differentiative state of the particular B cell group. Thus there may be a more fundamental effect of the Dα162 K or Eα183K mutations than simply the defect in antigen presentation.
In summary, extensive data demonstrate that mutations in the third and fourth dimer of dimers contact region of I-A k strongly inhibit antigen presentation to three well-characterized T cell clones under various assay conditions. Statistical analyses of this inhibition in a large number of class II mutants show mutations at different sites have consistent relative effects on inhibition on antigen presentation to various T cells. Many details of these responses can be predicted by assuming that mutations interfere with class II interaction with another molecule. This interaction might be association, either spontaneous or triggered by TCR engagement, of class II αβ heterodimers into structures containing the dimer of dimers units described originally for HLA-DR1. Alternatively, inhibition of T cell activation is very strongly correlated with mutations at two α chain sites, Dα162 and Eα183, and much more weakly correlated with corresponding β chain substitutions at Hβ112 and Hβ113. This correlation might imply that these α chain sites help maintain some essential conformation of the α chain moiety of the αβ molecule which mutations can disrupt. That specific T cell clones and antigen presentation protocols are variously affected by particular mutations suggests that both these factors may help regulate antigen presentation through class II molecules.
